

Media Contacts: For MaxCyte: Anette Breindl, Ph.D.
Atkins + Associates
(858) 860-0266 x. 105
abreindl@irpr.com
For Angiogene: Susan Baldwin,
Vice President, Business Development
(514) 596-1111 x. 233
baldwin@angiogene.com

FOR IMMEDIATE RELEASE

**MAXCYTE AND ANGIOGENE ENTER INTO RESEARCH COLLABORATION
FOR CELL-BASED GENE THERAPY FOR CONGESTIVE HEART FAILURE**

*MaxCyte GT System selected for highly efficient non-viral gene transfer to improve
perfusion of damaged heart muscle*

Rockville, MD and Montreal, Quebec, Canada – July 10, 2002 – MaxCyte, Inc. and Angiogene Inc. announced today that they have entered into a research agreement to develop a non-viral, recuperative treatment for Congestive Heart Failure (CHF) caused by myocardial infarction. Under the agreement, Angiogene will use the MaxCyte GT™ cell loading system in its *AngioCell*™ program to load muscle precursor cells with a patented gene construct that stimulates blood vessel growth. The altered “angiocells” will then be tested by Angiogene *in vitro* and *in vivo* pre-clinical studies for their ability to stimulate blood vessel growth and improve cardiac function.

“We are enthusiastic about working with Angiogene on their *AngioCell*™ program for the treatment of Congestive Heart Failure,” said Douglas Doerfler, President and CEO of MaxCyte. “This collaboration is an excellent example of how MaxCyte’s cell loading technology has the potential for broad applications to give our partners competitive advantages in development of gene-based medicines.”

“Our *AngioCell*™ program offers the potential for an exciting, minimally invasive alternative to open heart surgery for those suffering from this debilitating disease,” said Francois Bergeron, President and CEO of Angiogene. “This agreement gives Angiogene access to a non-viral cell loading technology that can transform our *angiocells* effectively. The combination of safety, cost and efficiency makes this partnership with MaxCyte attractive for the development of our program.”

According to the American Heart Association, 7.7 million Americans annually suffer from myocardial infarction and 4.7 million Americans have CHF, a condition in which the heart cannot pump enough blood to the body's other organs. The cost of treating CHF is between \$20-\$50 billion a year. Angiogene’s *AngioCell*™ program is a pioneering recuperative approach that aims to improve the function of damaged tissue, rather than merely treat the symptoms of the disease. *AngioCell*™ is intended to restore the contractility of the heart tissue with a cell therapy treatment that transplants muscle

precursor cells loaded with a gene to enhance blood vessel growth. The therapy also improves the blood flow and oxygen uptake of the damaged heart by stimulating the growth of new blood vessels in the myocardium, through a process of therapeutic angiogenesis.

About MaxCyte

MaxCyte, Inc. is a clinical stage biotechnology company improving therapeutic gene transfer, identifying more targeted ways to deliver drugs, and accelerating the drug discovery process by developing and using new cell loading technologies. The MaxCyte GT™ flow electroporation system brings individualized cell loading to the clinic for the first time. MaxCyte can load large volumes of virtually any molecule, including drugs, nucleic acids and proteins, into any cell rapidly enough to enable on-site patient treatment. MaxCyte's biotechnology and pharmaceutical partners gain a competitive edge by using its customized cell loading technology for therapeutic and R&D applications. The company currently markets its MaxCyte GT system for drug discovery applications, which include high throughput target validation and *in vivo* biological assays for gene expression studies. Possible therapeutic applications include non-viral gene delivery and drug delivery via platelets and blood cells. MaxCyte's pipeline includes one therapeutic in Phase I clinical trials and therapeutics in preclinical development. MaxCyte is majority owned by EntreMed, Inc. (NASDAQ: ENMD). For more information, visit <http://www.maxcyte.com>.

About Angiogene

Angiogene, Inc. is focused on building a product pipeline aligned with current and future trends in interventional cardiology and radiology through a well tailored combination of the most performing delivery devices with potent proprietary compounds. Angiogene's technology focuses on three discovery programs. The *SealantCoil* program is focused on the treatment of cerebral aneurysms with coated endovascular devices; the *BrightStent* program focuses on the post-angioplasty prevention of restenosis (re-narrowing of arteries) using stents with anti-proliferative therapeutics delivered at a specific dose; and the *AngioCell* program is a cell and gene therapy program that aims to improve perfusion of the diseased myocardium in patients with severe congestive heart failure via minimally invasive therapy. Angiogene is a private Canadian biotechnology company, based in Montreal, Quebec. For more information, please visit us at <http://www.angiogene.com>.

About EntreMed

EntreMed, Inc. (NASDAQ: ENMD), The Angiogenesis Company®, is a clinical-stage biopharmaceutical company developing angiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with pharmaceutical and biotechnology companies, universities and government laboratories. EntreMed has three drug candidates in over 15 clinical trials, as well as a rich pipeline of new proteins, genes and small molecules under development and in preclinical studies. For further information, visit EntreMed's web site at www.entremed.com.

###